[HLBANK] YoY Annualized Quarter Result on 31-Dec-2023 [#2]

Announcement Date
28-Feb-2024
Admission Sponsor
-
Sponsor
-
Financial Year
30-Jun-2024
Quarter
31-Dec-2023 [#2]
Profit Trend
QoQ- 2.82%
YoY- 4.65%
View:
Show?
Annualized Quarter Result
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Revenue 5,717,658 5,972,434 5,502,218 5,497,878 4,905,272 4,782,390 4,814,370 2.90%
PBT 5,168,184 4,949,078 4,237,298 3,411,078 3,407,042 3,348,672 3,226,982 8.16%
Tax -932,750 -901,958 -1,043,608 -611,694 -626,258 -560,350 -582,904 8.14%
NP 4,235,434 4,047,120 3,193,690 2,799,384 2,780,784 2,788,322 2,644,078 8.16%
-
NP to SH 4,235,434 4,047,120 3,193,690 2,799,384 2,780,784 2,788,322 2,644,078 8.16%
-
Tax Rate 18.05% 18.22% 24.63% 17.93% 18.38% 16.73% 18.06% -
Total Cost 1,482,224 1,925,314 2,308,528 2,698,494 2,124,488 1,994,068 2,170,292 -6.15%
-
Net Worth 35,533,145 32,079,791 30,062,673 28,251,912 26,051,994 24,468,126 23,197,104 7.36%
Dividend
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Div 1,024,600 860,377 737,231 605,164 654,881 654,665 654,592 7.74%
Div Payout % 24.19% 21.26% 23.08% 21.62% 23.55% 23.48% 24.76% -
Equity
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Net Worth 35,533,145 32,079,791 30,062,673 28,251,912 26,051,994 24,468,126 23,197,104 7.36%
NOSH 2,167,718 2,167,718 2,167,718 2,167,718 2,167,718 2,167,718 2,167,718 0.00%
Ratio Analysis
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
NP Margin 74.08% 67.76% 58.04% 50.92% 56.69% 58.30% 54.92% -
ROE 11.92% 12.62% 10.62% 9.91% 10.67% 11.40% 11.40% -
Per Share
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
RPS 279.02 291.55 268.68 268.55 239.69 233.76 235.35 2.87%
EPS 206.68 197.56 155.96 136.74 135.88 136.30 129.26 8.13%
DPS 50.00 42.00 36.00 29.56 32.00 32.00 32.00 7.71%
NAPS 17.34 15.66 14.68 13.80 12.73 11.96 11.34 7.33%
Adjusted Per Share Value based on latest NOSH - 2,167,718
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
RPS 278.92 291.35 268.41 268.20 239.29 233.29 234.85 2.90%
EPS 206.61 197.43 155.79 136.56 135.65 136.02 128.98 8.16%
DPS 49.98 41.97 35.96 29.52 31.95 31.94 31.93 7.75%
NAPS 17.3337 15.6491 14.6651 13.7818 12.7086 11.936 11.316 7.36%
Price Multiplier on Financial Quarter End Date
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Date 29/12/23 30/12/22 31/12/21 31/12/20 31/12/19 31/12/18 29/12/17 -
Price 18.90 20.56 18.62 18.20 17.30 20.40 17.00 -
P/RPS 6.77 7.05 6.93 6.78 7.22 8.73 7.22 -1.06%
P/EPS 9.14 10.41 11.94 13.31 12.73 14.97 13.15 -5.87%
EY 10.94 9.61 8.38 7.51 7.85 6.68 7.60 6.25%
DY 2.65 2.04 1.93 1.62 1.85 1.57 1.88 5.88%
P/NAPS 1.09 1.31 1.27 1.32 1.36 1.71 1.50 -5.18%
Price Multiplier on Announcement Date
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Date 28/02/24 28/02/23 28/02/22 26/02/21 26/02/20 26/02/19 26/02/18 -
Price 19.62 20.54 20.08 18.00 15.20 21.30 18.52 -
P/RPS 7.03 7.05 7.47 6.70 6.34 9.11 7.87 -1.86%
P/EPS 9.49 10.40 12.88 13.16 11.19 15.63 14.33 -6.63%
EY 10.53 9.62 7.77 7.60 8.94 6.40 6.98 7.08%
DY 2.55 2.04 1.79 1.64 2.11 1.50 1.73 6.67%
P/NAPS 1.13 1.31 1.37 1.30 1.19 1.78 1.63 -5.92%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment